ReCor Medical announced that the RADIANCE-HTN SOLO study met its primary efficacy endpoint and demonstrated a statistically significant reduction in blood pressure in hypertensive patients. In...
Hypertension
This page includes news and new technology on hypertension. The condition is caused by abnormally high blood pressure that causes excess force and pressure of the blood against the artery walls. Long-term, this can cause damage the vessels and contributes to heart disease. Therapies include antihypertensive medications such as diuretics and renal denervation therapy.
-
-
At the 2018 EuroPCR Annual Meeting in Paris, Medtronic announced first-ever-data from the SPYRAL HTN-ON MED Study. Initial study results found statistically significant and clinically important...
-
Medtronic plc announced U.S. Food and Drug Administration (FDA) approval to begin an investigational device exemption (IDE) pivotal trial to evaluate the Symplicity Spyral renal denervation system...
-
There were several notable presentations of new data on cardiovascular technologies at the recent 2018 American College of Cardiology (ACC) meeting.
News | Hypertension | July 05, 2018
July 5, 2018 — Physician practices now have access to new resources to improve their standard of quality care for...
News | Mobile Devices | June 13, 2018
June 13, 2018 — Medication management platform Medisafe released data showing that, on average,...
News | Renal Denervation | May 30, 2018
May 31, 2018 – ReCor Medical announced that the RADIANCE-HTN SOLO...
An example of renal denervation therapy being delivered. A catheter is inserted into the renal artery to ablate the nerves in the vessel wall that regulate vasoconstriction. This leaves the vessel permanently in the widest open position to allow greater blood flow to the kidneys.
Feature | Renal Denervation | May 30, 2018
May 30, 2018 — Despite the best efforts of clinicians to manage hypertension, it continues to increase and is now...
News | Renal Denervation | May 23, 2018
May 23, 2018 – At the 2018 EuroPCR Annual Meeting in Paris, Medtronic announced first-ever-data from the SPYRAL HTN-...
News | Renal Denervation | April 16, 2018
April 16, 2018 — Medtronic plc announced U.S. Food and Drug Administration (FDA) approval to begin an...
News | Hypertension | April 05, 2018
April 5, 2018 — YMCA of the USA (Y-USA) and the American Heart Association (AHA) are combining efforts to help more...
A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC.18. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at this year's conference.
Feature | ACC | March 27, 2018 | Dave Fornell
There were several notable presentations of new data on cardiovascular technologies at the recent 2018 American...
Image from presentation, "A Cluster-Randomized Trial of Blood-Pressure Reduction in Black Barbershops," Victor et al
News | ACC | March 20, 2018
March 20, 2018 — African-American men who received medical intervention aimed at controlling their...
News | Hypertension | February 16, 2018
February 16, 2018 — California’s Petaluma Health Center (PHC) was recently awarded a 2017 Healthcare Information and...
News | Womens Cardiovascular Health | December 06, 2017
December 6, 2017 — Women who develop high blood pressure during pregnancy are more likely to experience heart...
News | Hypertension | November 16, 2017
November 16, 2017 — Findings from a landmark study funded by the National Institutes of Health (NIH) support a key...
News | Hypertension | September 14, 2017
September 14, 2017 — Marijuana use is associated with a three-fold risk of death from...
